Cartesian Therapeutics Cash, Cash Equivalents, And Restricted Cash Of $88.9M And Net Proceeds From $130M Pipe Financing Are Expected To Support Development Of Descartes-08 In Myasthenia Gravis; End-of-phase 2 Meeting With FDA Expected By Year-end
Cartesian Therapeutics Cash, Cash Equivalents, And Restricted Cash Of $88.9M And Net Proceeds From $130M Pipe Financing Are Expected To Support Development Of Descartes-08 In Myasthenia Gravis; End-of-phase 2 Meeting With FDA Expected By Year-end
Cartesian Therapeutics現金、現金等價物和限制性現金總額達到8890萬美元，並預計淨收益13000萬美元的管道融資將支持Descartes-08在肌無力症方面的開發；預計在年底與FDA舉行2期末會議。
Cartesian Therapeutics Cash, Cash Equivalents, And Restricted Cash Of $88.9M And Net Proceeds From $130M Pipe Financing Are Expected To Support Development Of Descartes-08 In Myasthenia Gravis; End-of-phase 2 Meeting With FDA Expected By Year-end
Cartesian Therapeutics現金、現金等價物和限制性現金總額達到8890萬美元，並預計淨收益13000萬美元的管道融資將支持Descartes-08在肌無力症方面的開發；預計在年底與FDA舉行2期末會議。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。